Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
This is an early access version, the complete PDF, HTML, and XML versions will be available soon. Open AccessArticle by †, †, , , , , * and * Clinic and Research Center of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Shanghai 200433, China * Authors to whom correspondence should be addressed. † These authors contributed equally to this work.
Introduction The treatment of Multidrug-resistant Tuberculosis (MDR-TB) and Rifampin-resistant TB is challenging for TB control due to poor treatment outcomes, poor patient compliance, difficult management, more adverse events (AEs), high costs, and a lengthy period of treatment. In recent ten years, WHO reported that the average treatment success for MDR-TB worldwide was 50–60%,1–3 which was slowly improved.
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
